HDAX Therapeutics

Profile

HDAX Therapeutics develops next-gen HDAC6 inhibitors for cardiorenal and neurological diseases, with autosomal dominant polycystic kidney disease (ADPKD) as the lead indication. Its proprietary 2-site binding mechanism resolves the core limitations of current compounds, delivering best-in-class potential in a space attracting significant deal activity from top 3 pharma and leading VCs. HDAX has successfully raised $4M in pre-seed/seed financing in 2024, and is now raising a pre-A round, with commitments already in hand, including existing investors, for first-in-human readiness.

hdax therapeutics
hdaxtx.com

Contact

Event details

Date: June 22 - 25, 2026

Event contact

Patricia Cosgrove
Senior International Market Consultant
U.S.A. & Europe

Participants

23 in total
  • 20/20 OptimEyes Technologies
    20/20 OptimEyes Technologies is developing OPT-101, a once-weekly, non-invasive glaucoma eye drop designed to…
  • Altis Labs
    Altis Labs is the computational imaging company accelerating clinical trials with AI endpoints.…
  • BioScript Solutions
    BioScript Solutions is a Canadian healthcare company committed to simplifying access to specialty care. BioScript…
  • Biotherapeutics Manufacturing Centre
    The Ottawa Hospital's Biotherapeutics Manufacturing Centre(BMC) is a cell and gene therapy…
  • Custom Biologics
    Custom Biologics provides regulatory compliant potency testing and assay services for all phases of…
  • Dalriada Drug Discovery
    Dalriada is a Canadian small molecule discovery company focusing on unlocking challenging and undruggable targets…
  • Eurofins CDMO Alphora
    Located in Mississauga, Ontario, Eurofins CDMO Alphora delivers comprehensive solutions for small…
  • Everest Clinical Research
    Founded in 2004, Everest Clinical Research is a full-service contract research organization with more than 750…
  • HDAX Therapeutics
    HDAX Therapeutics develops next-gen HDAC6 inhibitors for…
  • i-RNA Corporation
    i-RNA Corporation is a preclinical biotech developing siRNA…
  • ImmunoBiochem Corporation
    ImmunoBiochem is a pharma-partnered biotech developing novel degrader-antibody conjugate (DAC)…
  • Medicenna Therapeutics
    Medicenna is a clinical stage immunotherapy company developing novel and highly differentiated engineered long-…
  • Noa Therapetuics
    Noa Therapeutics is pioneering a breakthrough to the Aryl Hydrocarbon Receptor (AhR), a commercially…
  • Nucro-Technics
    Nucro-Technics is a full-service Contract Support Organization that specializes in the conduct of both…
  • Paradox Immunotherapeutics
    Paradox Immunotherapeutics is a venture-backed, clinical-inflection biotech tackling protein misfolding diseases…
  • PharmAla Biotech
    PharmAla Biotech (CSE:…
  • PlantForm Corporation
    PlantForm develops and manufactures proteins, antibodies, and vaccines at low cost using its green, plant-based…
  • Q&C Services
    For over 32 years, Q&C Services has been Canada’s largest privately owned pharmaceutical consulting firm. Its…
  • QurCan Therapeutics Inc.
    QurCan Therapeutics is advancing the next wave of genetic medicines for CNS…
  • Spiderwort Biotechnologies Inc.
    Spiderwort Biotechnologies is a clinical-stage regenerative medicine company pioneering a differentiated class of…
  • Sussex Research Laboratories Inc.
    Sussex Research Laboratories Inc. (Ottawa, Canada) is a globally recognized specialist in Empowering Therapeutic…
  • SYNG Pharmaceuticals Inc
    SYNG has developed, EndoID a new first-in-class diagnostic test for Endometriosis. It is…
  • YYZ Pharmatech Inc.
    YYZPharmatech Inc. (“YYZ”) reveals and validates novel, proximal, functional co-receptor drug…